Targeting senescent cholangiocytes and activated fibroblasts with B‐cell lymphoma‐extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2−/− ) mice
Anja Moncsek(University Hospital of Zurich), Joachim C. Mertens(GastroZentrum Hirslanden Zürich), Nicholas F. LaRusso(Mayo Clinic), Christy E. Trussoni(Mayo Clinic), Eleonora Patsenker(University Hospital of Zurich), Patrick L. Splinter(Mayo Clinic in Arizona), Tamar Tchkonia(Cedars-Sinai Medical Center), Steven P. O’Hara(Mayo Clinic in Arizona), Beat Müllhaupt(University Hospital of Zurich), Achim Weber(University Hospital of Zurich), Camille Zuber(University Hospital Zurich), Yi Zhu(University of Macau), Piero V. Valli(University Hospital of Zurich), Christian D. Fingas(Essen University Hospital), Gregory J. Gores(Mayo Clinic in Arizona), Mohammed Alsuraih(Mayo Clinic), James L. Kirkland(Cedars-Sinai Medical Center)
Cited by 133
Related Papers
Hepatocellular carcinoma
|Nature Reviews Disease Primers|2016|2.7k
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
|Nature Reviews Gastroenterology & Hepatology|2020|2.5k
The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs
|Aging Cell|2015|2.4k
Cholangiocarcinoma — evolving concepts and therapeutic strategies
|Nature Reviews Clinical Oncology|2017|1.7k
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
|JNCI Journal of the National Cancer Institute|2008|1.7k